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in a Meta-AnalysisWe thank Dr. Jin and colleagues for their comments and interest in
our paper (1). They disagreed with the meta-analysis of data from 2
randomized, controlled trials (RCTs) combined with those from an
observational study in our analysis of controlled studies. Our
decision to pool these data is supported by an opinion paper
published in the American Journal of Epidemiology (2). Moreover,
the pooled data for these 3 studies was consistent; all 3 included
studies demonstrated statistically signiﬁcant beneﬁts with renal
artery denervation (RDN) and their meta-analyses produced I2
measures ranging from 0% to 60%. We agree that the included
studies were of variable quality, but we preferred to include allavailable data. In doing so, we provided the reader with a more
complete understanding of the current state of this literature.
Dr. Jin and colleagues also point out typographical errors in
Figure 2. They are correct that the numbers across the rows for
Symplicity HTN-2 and the Pokushalov et al. (3) study were
inverted for the 6-month systolic blood pressure (BP) analysis.
However, this labeling error had no effect on the results of our meta-
analysis. There was an error in the SD in the study by Pokushalov
et al. (3) in our Figure 2, but re-analysis revealed that this did not
appreciably affect our results. In addition, Jin et al. correctly iden-
tiﬁed a typographical error where the sentence should read “follow-
up rate of <70% at 6 months” instead of “>70%.” With regard to
SYMPLICITY HTN-1, the data were obtained from Table 1,
which included the baseline BP and SD, and Figure 1A, which
provided the change in BP at each time interval with the corre-
sponding 95% conﬁdence interval (4).
We acknowledged in our paper that the available literature con-
sisted of many small studies and discussed the need for further RCTs
in this area. We also acknowledged that the analysis of uncontrolled
studies included studies with ambulatory BP measurements and
studies with ofﬁce BP measurements. This variability in BP
measurement was reported in Table 1 of our paper and was the
rationale behind sensitivity analyses restricted to studies that exam-
ined ambulatory BP response.
The goal of our systematic review andmeta-analysis was to present
and analyze the currently available data regarding the efﬁcacy and
safety of this intervention to allow operators and programs to make
informed decisions regarding the appropriateness of its use in
patients with resistant hypertension. Our conclusion was not that
RDN should be used in routine clinical practice but rather that there
remains a need for large RCTs with long-term follow-up to conﬁrm
and build on the observed efﬁcacy and safety of RDN.Mark I. Davis, MD
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